Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YTS109 Cell Therapy in Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT07287930Phase 1Not yet recruiting
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of YTS-109 in autoimmune hemolytic anemia (AIHA). Primary endpoints: Dose Limiting Toxicity at 28 days and Treatment-Emergent Adverse Events at 6 months. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
YTS-109
03
Conditions
autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on NCT07287930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07287930.